The stock of Apogee Therapeutics Inc (NASDAQ:APGE) last traded at $39.48, down -2.18% from the previous session.
APGE stock price is now 5.98% away from the 50-day moving average and -10.86% away from the 200-day moving average. The market capitalization of the company currently stands at $2.35B.
With the price target of $95, Citigroup recently initiated with Buy rating for Apogee Therapeutics Inc (NASDAQ: APGE). On November 25, 2024, Canaccord Genuity recently initiated its ‘Buy’ rating on the stock quoting a target price of $89, while ‘BofA Securities’ rates the stock as ‘Buy’
In other news, Dambkowski Carl, Chief Medical Officer sold 2,725 shares of the company’s stock on May 07 ’25. The stock was sold for $97,419 at an average price of $35.75. Upon completion of the transaction, the Chief Medical Officer now directly owns 244,448 shares in the company, valued at $9.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 02 ’25, Chief Medical Officer Dambkowski Carl sold 3,860 shares of the business’s stock. A total of $139,801 was realized by selling the stock at an average price of $36.22. This leaves the insider owning 247,173 shares of the company worth $9.76 million. A total of 37.33% of the company’s stock is owned by insiders.
During the past 12 months, Apogee Therapeutics Inc has had a low of $26.20 and a high of $63.50. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 15.82, and a quick ratio of 15.82.
The company reported revenue of $63.1 million for the quarter, compared to $38.18 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 65.25 percent.
